Solid pseudopapillary neoplasm (SPN) is an extremely rare pancreatic epithelial neoplasm with low malignancy that affects mainly young females. It is characterized by a good prognosis, even in the presence of metastases. SPNs have a particular avidity for 18Ffluorodeoxyglucose (18F-(FDG)). Nonetheless, there are very few papers in the literature on the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-(FDG) PET/CT) in the diagnosis and staging of SPNs. A 23-year-oldwomanpresented to our attention with gastric outlet obstruction due to a bulky solid pseudopapillary neoplasm of the pancreatic head. A 18F-(FDG) PET/CT showed a marked 18F-(FDG) uptake at the pancreatic head with no abnormal metabolic activity in other abdominal organs. Given the particular avidity for 18F-(FDG), SPNs can be easily recognized on 18F-(FDG) PET/CT. However, this exam is not useful in differentiating this neoplasm from other malignant pancreatic solid lesions, but it could give a contribution to the staging by the ability to identify potential metastases or recurrences.

Vaccination against coronavirus disease 2019 (COVID-19) started in early December 2020 worldwide, and healthcare workers in Japan were vaccinated in February 2021. We encountered three patients who underwent 18Ffluorodeoxyglucose ((FDG)) positron emission tomography/computed tomography (PET/CT) for cancer screening at our institution, showing (FDG) uptakes in the axillary lymph nodes, which seemed to be reactive changes. Two of them were males in their 40s and one was a female in her 50s,all of them were healthcare workers. The medical history revealed that they received the Pfizer-BioNTech COVID-19 vaccination twice at their left shoulders before the (FDG) PET/CT examination. The degree of (FDG) uptakes were maximum standardized uptake value (SUVmax)=3. 2–, 9. 9, SUVmax=5. 9–, 10. 3, and SUVmax=2. 8–, 7. 9, respectively. They were diagnosed with reactive lymph nodes because of vaccination owing to the absence of abnormal (FDG) PET/CT findings at other sites. As COVID-19 vaccination becomes more widespread in Japan, radiologists should be aware of these findings to avoid misdiagnosis of (FDG) uptakes in pathological lymph nodes and to prevent unnecessary additional examinations. Recently, similar (FDG) PET/CT findings have been reported after receiving the COVID-19 vaccination, and we will report it with a literature review.

Hypersensitivity pneumonitis (HP) is an interstitial lung disease resulting from an immune-mediated response in susceptible and sensitized individuals to various inhaled antigens in the environment. Imaging diagnosis is usually based on highresolution CT findings. Here, we present a 49-year-old man with a history of diffuse large B-cell lymphoma presented with fever and occasional cough. 18Ffluorodeoxyglucose ((FDG)) positron emission tomography/computed tomography (PET/CT) revealed diffuse (FDG) uptake in the bilateral lungs. Expiratory low-dose CT simultaneously performed in PET scanning revealed centrilobular nodules and air trapping in ground glass opacities (GGO). Our imaging diagnosis was acute hypersensitivity pneumonitis (HP). Based on the results of his clinical course, blood laboratory tests, and bronchoscopy, he was diagnosed with acute HP. Diffuse pulmonary (FDG) uptake can be seen in the patients with acute HP. In addition, expiratory low-dose CT findings of centrilobular nodules and air trapping in GGO may be helpful for accurate diagnosis of acute HP.

Concentration of kryptofix 2.2.2 in [18F] (FDG) solutions and standard solutions of kryptofix 2.2.2 was determined by two methods: Visualization of combination of K2.2.2 with iodine vapor and iodoplatinate reagent. In both methods, concentration difference of K2.2.2 solutions was appeared as difference in color intensity of revealed spots on TLC. The detection limit of K2.2.2 by iodine vapor and iodoplatinate reagent is 25 and 2 ppm, respectively. Both methods can be used to release or reject the quality of [18F] (FDG) radiopharmaceutical for intravenous injection, but the second method is more suitable because of taking shorter time.

Introduction: According to the World Health Organization (WHO) classification Lymphoid neoplasms are categorized into 3 major groups: Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL) of B-cell or T-cell/natural killer (NK) cell origin.Few dedicated reports have been published about metabolic imaging by (FDG)-PET CT in different subtypes of NHL accordig to who classification.Objective: Determine the reliability of (FDG)-PET-C Tin detection of different subtypes of NHL according to using the WHO classification.Materials and Methods: In a total of 164 patients with a histological proven non-Hodgkin lymphoma, (FDG)-PET/CT imaging was performed for staging (n=138) and restaging (n=26). (FDG)-uptake pattern according to different lymphoma subtypes was qualitatively evaluated.Results: Distinctive (FDG)-uptake could reliably be seen in one site of all patients with DLBCL (n=77), mediastinal large b-cell lymphoma (n=12), mantel cell lymphoma (n=5), PTLD (n=5), anaplastic large cell (t cell) lymphoma (n=6), precursor B lymphoblastic lymphoma (n=1), plasmacytoma of sternum (n=2), splenic marginal zone lymphoma (n=1),  precursor t lymphoblastic lymphoma of thymus (n=1), extranodal NK/t cell NHL NASAL type (n=3), primary cutaneous anaplastic large cell (t cell) lymphoma (n=2), angioimmuoblastic t cell lymphoma (n=1) and Burkitt lymphoma (n=2). One case of small lymphocytic lymphoma and one case of CLL were not detected by PET/CT. Evaluation of follicular lymphoma (86% positive) and MALT lymphoma (83% positive) revealed less reliable results.Conclusion: T-cell lymphomas and most B-cell lymphomas can be reliably evaluated by (FDG)-PET/CT imaging.

Background: The purpose of this study is to evaluate the accuracy of 18Ffluorodeoxyglucose ((FDG)) positron emission tomography/Computed Tomography (PET/CT) in predicting tumor prognosis in patients with Small Cell Lung Cancer (SCLC). Materials and Methods: From July 2015 to March 2019, all 30 SCLC patients who had analyzable PET/CTs and adequate clinical data were evaluated. Medical records were retrospectively reviewed, including age, gender, stage, performance status according to the Eastern Cooperative Oncology Group (ECOG), metabolic parameters on PET and treatment programs. Factors potentially affecting tumor prognosis were examined by models of univariate and multivariate Cox proportional hazards regression. Results: The median age of the cohort was 58 years (range: 39-93). A median follow-up period of 12 months was observed. Multivariate Cox proportional hazards regression demonstrated that the overall survival (OS) (p = 0. 03) and progression-free survival (PFS) (p = 0. 014) were related only to the metabolic tumor volume (MTV). The optimal cutoff threshold was 98 mm3, and the receiver operating characteristic (ROC) curve had an area under it of 0. 75. In comparison to the high-MTV group, the low-MTV group had statistically substantially prolonged OS (p = 0. 004) and PFS (p < 0. 001). Conclusion: The MTV of 18F-(FDG) PET/CT is a major independent prognostic factor in SCLC patients and has significant implications for OS and PSF.